[Critical considerations on the method of action of 2-(2,6-dichlorophenylamino)-2-imidazoline-hydrochloride].
D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D001949:Bretylium Compounds / Q000494:pharmacology; D002415:Cats; D006145:Guanethidine / Q000494:pharmacology; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D007545:Isoproterenol / Q000494:pharmacology; D008750:Methyldopa / Q000494:pharmacology; D051379:Mice; D010275:Parasympathetic Nervous System / Q000187:drug effects; D010646:Phentolamine / Q000494:pharmacology; D011817:Rabbits; D051381:Rats; D012110:Reserpine / Q000494:pharmacology; D013564:Sympathetic Nervous System / Q000187:drug effects
D000959:Antihypertensive Agents; D001949:Bretylium Compounds; D007093:Imidazoles; D008750:Methyldopa; D012110:Reserpine; D007545:Isoproterenol; D010646:Phentolamine; D006145:Guanethidine
Kritische Betrachtungen zum Wirkungsmechanismus des 2-(2,6-Dichlorphenylamino)-2-imidazolin-hydrochlorids.